1. Volume 92, Issue 1, Pages 248-257 (July 2017)
Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome 
Aditi Sinha, Aarti Gupta, Mani Kalaivani, Pankaj Hari, Amit K. Dinda, Arvind Bagga 
Kidney International 
Volume 92, Issue 1, Pages (July 2017)
DOI: /j.kint
Copyright © 2017 International Society of Nephrology Terms and Conditions

2. Figure 1
Study flow. All patients were included in the modified intention-to-treat analysis.
Kidney International  , DOI: ( /j.kint )
Copyright © 2017 International Society of Nephrology Terms and Conditions

3. Figure 2
Kaplan-Meier estimates of relapse free–survival (a) and survival free of treatment failure (b). Similar proportions of patients receiving mycophenolate mofetil (MMF) and tacrolimus were in sustained remission at 6 months (58.6% vs. 67.7%) and at 1 year (41.1% vs. 54.8%) (log rank P = 0.24). The proportions of patients with treatment failure were significantly higher for patients receiving MMF than tacrolimus at 6 months (31% vs. 0%) and 1 year (52% vs. 9.7%) (log rank P = ).
Kidney International  , DOI: ( /j.kint )
Copyright © 2017 International Society of Nephrology Terms and Conditions

4. Figure 3
Subgroup analysis of patients treated with mycophenolate mofetil versus tacrolimus in the entire group and in subgroups defined a priori and potential confounders. Plots for relative risk of favorable outcome (a) and hazard ratio for treatment failure (b) demonstrate a significantly lower relative risk of favorable outcome and increased risk of treatment failure in most subgroups. *Hazard ratio could not be computed because of lack of events in the tacrolimus group.
Kidney International  , DOI: ( /j.kint )
Copyright © 2017 International Society of Nephrology Terms and Conditions